| Name | AC1-IN-1 |
|---|
| Description | AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.54 µM (AC1)[1] |
| In Vitro | AC1-IN-1 (compound 38; HEK293 cells; 30 µM, 1 hours) shows nontoxic to this human cell line[1]. Cell Cytotoxicity Assay[1] Cell Line: HEK293 cells Concentration: 30 µM Incubation Time: 1 hours Result: Showed nontoxic to HEK293 cells. |
| In Vivo | AC1-IN-1 (5.6 mg/kg; i.v.) displays modest, yet statistically significant, antiallodynic effects at 1 h post-treatment compared to the 0 min (allodynic) time point[1]. Animal Model: Male and female C57BL/6N mice (complete Freund’s adjuvant inflammatory pain model)[1] Dosage: 5.6 mg/kg (dissolved in 10% DMSO/10% Cremaphor/80% saline) Administration: Intravenous injection; 2 hours Result: Displayed modest, yet statistically significant, antiallodynic effects. |
| References |
| Molecular Formula | C18H18FN5O2 |
|---|---|
| Molecular Weight | 355.37 |